Paul M Hassoun
Overview
Explore the profile of Paul M Hassoun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
265
Citations
8543
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mukherjee M, Rudski L, Addetia K, Afilalo J, DAlto M, Freed B, et al.
J Am Soc Echocardiogr
. 2025 Mar;
38(3):141-186.
PMID: 40044341
Right heart adaptation to pulmonary hypertension (PH) is a critical determinant of clinical outcomes, morbidity, and mortality in patients with or at risk for cardiopulmonary disease. The World Symposium on...
2.
Yogeswaran A, Funderich M, Olschewski H, Kovacs G, Kiely D, Lawrie A, et al.
ERJ Open Res
. 2025 Feb;
11(1).
PMID: 40008170
Introduction: The definition of pulmonary hypertension (PH) was recently changed and led to a new subset of PH patients with mildly impaired pulmonary haemodynamics, characterised by a mean pulmonary artery...
3.
Sivakumar N, Zhang C, Chang-Chien C, Gu P, Li Y, Yang Y, et al.
Pulm Circ
. 2025 Feb;
15(1):e70057.
PMID: 39990646
Although right ventricle (RV) dysfunction drives clinical worsening in pulmonary hypertension (PH), information about RV function has not been well integrated in PH risk assessment. The gold standard for assessing...
4.
Rahaghi F, Humbert M, Hoeper M, White R, Frantz R, Hassoun P, et al.
Lancet Respir Med
. 2025 Feb;
PMID: 39987941
Novel treatments in pulmonary arterial hypertension (PAH) with significant pathophysiological and clinical responses have generated renewed interest in changing the course of the disease and achieving long-term disease control. Historically,...
5.
Tiniakou E, Casciola-Rosen L, Thomas M, Manabe Y, Antar A, Damarla M, et al.
Clin Transl Immunology
. 2024 Dec;
13(12):e70019.
PMID: 39734590
Objectives: CD209L and its homologous protein CD209 act as alternative entry receptors for the SARS-CoV-2 virus and are highly expressed in the virally targeted tissues. We tested for the presence...
6.
Mukherjee M, Mathai S, Jellis C, Freed B, Yanek L, Agoglia H, et al.
Circ Cardiovasc Imaging
. 2024 Dec;
17(10).
PMID: 39691460
Background: Defining qualitative grades of echocardiographic metrics of right heart chamber size and function is critical for screening, clinical assessment, and measurement of therapeutic response in individuals with pulmonary vascular...
7.
Farha S, Asosingh K, Hassoun P, Barnard J, Comhair S, Reichard A, et al.
Antioxid Redox Signal
. 2024 Dec;
42(7-9):361-377.
PMID: 39655485
Alterations of mitochondrial bioenergetics and arginine metabolism are universally present and mechanistically linked to pulmonary arterial hypertension (PAH), but there is little knowledge of arginine metabolism and mitochondrial functions across...
8.
Shelburne N, Nian H, Beck G, Casanova N, Desai A, DuBrock H, et al.
CHEST Pulm
. 2024 Nov;
2(3).
PMID: 39524046
Background: Sex-based differences are important in the development and progression of pulmonary arterial hypertension. However, it is not established whether these differences are generalizable to all forms of pulmonary hypertension...
9.
Montovano M, Scheel 3rd P, Cubero Salazar I, Hassoun P, Tedford R, Hsu S
Pulm Circ
. 2024 Nov;
14(4):e70002.
PMID: 39507237
The discrimination between pre and postcapillary exercise-induced pulmonary hypertension relies on accurate measurement of pulmonary capillary wedge pressure, which can be unreliable. We found that exercise pulmonary artery compliance and...
10.
Tuhy T, Coursen J, Graves T, Patatanian M, Cherry C, Niedermeyer S, et al.
bioRxiv
. 2024 Nov;
PMID: 39484590
Introduction: Pulmonary arterial hypertension (PAH) involves progressive cellular and molecular change within the pulmonary vasculature, leading to increased vascular resistance. Current therapies targeting nitric oxide (NO), endothelin, and prostacyclin pathways...